The FDA has paused BioNTech’s phase 1/2a trial of its experimental malaria vaccine, BNT165e, due to unspecified concerns, the company confirmed in an SEC filing on Monday. BioNTech is working with the FDA to address the agency's requests, though specific details have not been disclosed. Both parties are collaborating to determine the next steps for the trial, which involves nearly 180 healthy, malaria-naïve adults. The study is expected to conclude in early 2026 and is assessing the vaccine’s safety, tolerability, efficacy, and immunogenicity.
BioNTech’s malaria vaccine initiative was first announced in 2021, using the same mRNA technology that powered its successful COVID-19 vaccine. The company’s Malaria Project aims to develop multiple vaccine candidates targeting malaria antigens, including circumsporozoite protein (CSP), and to establish mRNA manufacturing facilities in Africa for sustainable vaccine production. The initiative is part of the eradicateMalaria project, aiming to combat malaria’s global impact, particularly in sub-Saharan Africa, where the disease remains a leading cause of death.